Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

References

• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Patel H, Colombel J-F, et al. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017;45(2):264–275.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–321.
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s disease. Gastroenterology. 2019;157(4):997–1006.e6.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Ricart E, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48(8):839–851.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol. 2016;12(7):833–842.
   PubMed Web of Science ®Google Scholar
• Rogler G. Mechanism of action of vedolizumab: do we really understand it? Gut. 2019;68(1):4–5.
   PubMed Web of Science ®Google Scholar
• Zundler S, Neurath MF. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol. n.d.;33(4 Suppl 92):S19–28.
   PubMed Web of Science ®Google Scholar
• Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies. Immunotherapy. 2014;6(9):963–971.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52(6–7):722–729.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients. Inflamm Bowel Dis. 2015;21(12):2879–2885.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Mertens E, Dreesen E, et al. Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients. J Crohns Colitis. 2019;pii: jjz151. DOI:10.1093/ecco-jcc/jjz151.
   Web of Science ®Google Scholar
• Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(6):626–637.
   PubMed Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67(1):43–52.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.e5.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Van Assche G, et al. Vedolizumab as induction and maintenance therapy for Crohnʼs disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Loftus EV, Colombel J-F, et al. Long-term efficacy of vedolizumab for Crohn’s disease. J Crohn’s Colitis. 2016;109(4):jjw176.
   Google Scholar
• Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohn’s Colitis. 2016;11(4):jjw177.
   Google Scholar
• Ylisaukko-Oja T, Aaltonen J, Nuutinen H, et al. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a finnish nationwide inflammatory bowel disease cohort study (FINVEDO). Scand J Gastroenterol. 2018;53(2):158–167.
   PubMed Web of Science ®Google Scholar
• Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019;14(2):e0212989.
   PubMed Web of Science ®Google Scholar
• Cummings F, Gaya DR, Levison S, et al. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. Medicine (Baltimore). 2019;98(9):e14681.
   PubMed Web of Science ®Google Scholar
• Plevris N, Chuah CS, Allen RM, et al. Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the scottish vedolizumab cohort. J Crohn’s Colitis. 2019;13:1111–1120.
   Google Scholar
• Allegretti JR, Barnes EL, Stevens B, et al. Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab. Dig Dis Sci. 2017;62(6):1590–1596.
   PubMed Web of Science ®Google Scholar
• Szántó K, Molnár T, Farkas K. New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab. J Crohn’s Colitis. 2018;12(5):629.
   Google Scholar
• Sands BE, Van Assche G, et al. Vedolizumab in combination with corticosteroids for induction therapy in Crohn’s disease: a post hoc analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019;25(8):1375–1382.
   PubMed Web of Science ®Google Scholar
• Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019;157(4):1007–1018.e7.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel J, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.e3.
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127–1136.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Schwartz D, Danese S, et al. Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2. J Crohns Colitis. 2018;12(5):621–626.
   PubMed Web of Science ®Google Scholar
• Yamada A, Komaki Y, Patel N, et al. The use of vedolizumab in preventing postoperative recurrence of Crohn’s disease. Inflamm Bowel Dis. 2018;24(3):502–509.
   PubMed Web of Science ®Google Scholar
• Pouillon L, Rousseau H, Busby-Venner H, et al. Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis. J Crohn’s Colitis. 2019;13(8):970–975.
   Google Scholar
• Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018;47(7):906–912.
   PubMed Web of Science ®Google Scholar
• Hanžel J, Sever N, Ferkolj I, et al. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United Eur Gastroenterol J. 2019;7(6):741–749.
   PubMed Web of Science ®Google Scholar
• Singh S, Dulai PS, Vande Casteele N, et al. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019;50(8):848–857.
   PubMed Web of Science ®Google Scholar
• Al-Bawardy B, Ramos GP, Willrich MAV, et al. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(3):580–586.
   PubMed Web of Science ®Google Scholar
• Wyant T, Yang L, Lirio R, et al. P441 long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI programme). J Crohn’s Colitis. 2019;13(Supplement_1):S331–S331.
   Google Scholar